4. Möller JC et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005 May; 20(5): 602-10.
5. Rektorova I et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10(4): 399-406.
6. Reichmann H et al. Pramipexole in routine clinical practice. CNS Drugs 2003; 17(13): 965-973.
7. Lemke MR et al. Depression and Parkinson's disease. J Neurol 2004 Sep;251 Suppl 6:VI/24-7.
8. Lemke MR et al. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005 Spring; 17(2): 214-20.
9. Rektorova I et al. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 2005; 12: 9-15.
10. Goldberg JF et al. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004 Mar; 161(3): 564-6.
11. Künig G et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharm 1999; 22: 301-305.
12. eentjens A et al. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009 Jan;31(1):89-98.
13. Barone P et al. Depression and antidepressant use in Parkinson's disease: Results from the PRODEST-PD study. Abstract P1122 poster presented at 11th Congress of EFNS, Brussels, 26 Aug 2007.
14. Barone P et al. Depressive symptoms in Parkinson's disease: Design and methods of an observational study. Mov Disord. Vol. 21, Suppl. 15, 2006: S476.
15. Nussbaum R et al. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64.
16. de Rijk MC et al. Prevalence of Parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry.
17. Parkinson Study Group, Holloway RG et al. Pramipexole vs levodopa as initial treatment for Parkinson disease. Arch Neurol 2004; 61(7): 1044-1053.
18. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35.
Contact: Ursula Bardon, Corporate Division Communications, Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, Phone: + 49-6132-77-2622, Fax: + 49-6132-72-2622, Email: press@boehringer-ingelheim.com
